Proposed staged framework for oral glutamatergic and senescence-modulating strategies in treatment-resistant depression
This abstract-only article proposes, without reporting original data, a staged research framework for oral dextromethorphan with a CYP2D6 inhibitor plus piracetam, and later NMN plus NAC and a senescence-directed agent, in a biomarker-enriched subset of unipolar treatment-resistant depression. [1]
Automatic summary · not editorially reviewed
The key findings
The article is a translational hypothesis and drug-development framework that reports no original clinical or laboratory data and is not a systematic review. [1]
The core regimen is defined as dextromethorphan, one prespecified CYP2D6 inhibitor and piracetam; glutamine is only an optional exploratory component. [1]
No clinical role can yet be assigned to any proposed combination, and none should be used outside formal research protocols. [1]
The source at a glance
- Study type / format
- Abstract of a proposed translational hypothesis and drug-development framework; no original data, not a systematic review.
- Population / context
- People with unipolar treatment-resistant depression, defined as non-remission after at least two adequately delivered antidepressant trials, in a proposed biomarker-enriched subset.
- Summary based on
- Study abstract
- Original publication
- August 24, 2026
Proposed framework for unipolar treatment-resistant depression
The article defines treatment-resistant depression as non-remission after at least two adequately delivered antidepressant trials, while noting that this population is biologically heterogeneous. It explicitly presents a translational hypothesis and drug-development framework: it reports no original clinical or laboratory data and is not a systematic review. The central hypothesis concerns an oral regimen of dextromethorphan, one prespecified CYP2D6 inhibitor and piracetam, which could, if pharmacokinetically and clinically validated, initiate glutamatergic plasticity. Glutamine is only an optional exploratory component and is not part of the core or augmentation definition for future testing.
Supporting source [1]
Uneven evidence for NAC, NMN and senolytics
The framework positions NMN plus N-acetylcysteine (NAC) as a later evaluation step, followed only at a later stage by a candidate senescence-directed agent, for effects on the redox, bioenergetic, inflammatory and cellular-aging context linked to response durability in a biomarker-enriched subset. The author describes existing evidence as uneven: human studies show that CYP2D6 phenotype and inhibition materially alter dextromethorphan exposure; NAC has heterogeneous adjunctive psychiatric evidence; NMN has human NAD-related target-engagement data without established antidepressant efficacy; and senolytics have limited early human data outside treatment-resistant depression. Dasatinib plus quercetin is therefore placed as a later-stage, specialist-supervised research probe, not routine psychiatric augmentation.
Supporting source [1]
No clinical role yet for any proposed combination
The proposed development sequence prioritizes pharmacokinetic characterization, safety, target engagement, biomarker-defined subgroup selection, controlled efficacy testing and independent replication. The author states that no clinical role can yet be assigned to any proposed combination and that none should be used outside formal research protocols. Because this is an abstract, the full text was not reviewed; the abstract reports no original data, so the framework's hypotheses and the cited evidence remain unverified here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The article reports no original clinical or laboratory data and is not a systematic review, so its hypotheses and cited evidence are not independently verified here.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Cheung N. · europepmc.org · August 24, 2026